Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for ...
Please provide your email address to receive an email when new articles are posted on . Two formulations of once-yearly injectable lenacapavir for PrEP were safe, well tolerated and generated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results